STOCK TITAN

Exicure Announces Strategic Expansion into Parkinson’s Disease

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Exicure (XCUR) signed a Parkinson’s disease device expansion agreement with NeuroQ Biologics and Laonz focused on X-CUE augmented-reality smart glasses. Under the November 19 agreement, Exicure intends to acquire a 20% to 100% stake in NeuroQ, primarily by issuing Exicure common shares for NeuroQ shares held by Laonz. Final terms require subsequent written agreements and are subject to applicable corporate and regulatory approvals and Nasdaq requirements.

Laonz completed the transfer of the X-CUE business and related rights to NeuroQ, which will lead clinical evaluation and commercialization efforts. The developers say the latest version is ready for planned trials, with an anticipated clinical evaluation period of approximately six months. After the proposed acquisition closes, Exicure intends to provide up to US$500,000 in development funding, subject to approvals, funding availability and definitive funding arrangements.

Loading...
Loading translation...
6 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointSigned agreement with NeuroQ and Laonz expands Exicure’s business plans into medical devices for Parkinson’s disease
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Proposed NeuroQ investment would give Exicure a 20% to 100% equity stake
  • Minor pointX-CUE business transfer to NeuroQ is complete and includes related intellectual property, technology, assets and business rights
  • Minor pointX-CUE’s third revision has completed product development and is ready for planned trials, the developers say
  • Minor point. Forward-looking: it has not happened yet and may not happen.Clinical evaluation is anticipated to take approximately six months, the developers say
  • Minor point. Forward-looking: it has not happened yet and may not happen.NeuroQ will lead further development, clinical evaluation, regulatory approval efforts and commercialization, with support from Exicure

Negative

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Proposed Exicure common share issuance would dilute existing holders and serve as the primary consideration for Laonz’s NeuroQ shares
  • Moderate pointFinal stake, exchange ratio and other acquisition terms remain subject to subsequent written agreements, applicable approvals and Nasdaq requirements
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Planned development spending of up to US$500,000 depends on acquisition completion, applicable approvals, funding availability and definitive funding arrangements 7.8% of market cap
Argus 15 min delay 2 alerts
-7.00% vs previous close $0.9114 last price 0.8x rel. volume Open Argus
Details

Market Reaction – XCUR

$0.91 – $1.00 Day Range
$5.97M Mkt Cap at Last Price

On Nov 20, the day this news came out, the latest delayed price for XCUR is 7.00% below the previous close. Our momentum scanner has recorded 2 alerts for this stock so far that day. The latest delayed price is $0.91.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Proposed NeuroQ equity interest: 20% to 100% Development funding: up to US$500,000 Clinical evaluation period: approximately six months
Proposed NeuroQ equity interest
20% to 100%
Final acquisition percentage and other terms remain to be determined
Development funding
up to US$500,000
Intended after completion of the proposed share acquisition, subject to approvals and funding arrangements
Clinical evaluation period
approximately six months
Anticipated evaluation period for X-CUE

Key Terms

freezing of gait
1 terms
freezing of gait medical
"freezing of gait, a condition that can significantly affect mobility"
A brief, episodic inability to start or continue walking despite the intention to do so; the feet feel as if they are glued to the floor and normal stepping is interrupted. It is a symptom commonly seen in movement disorders (most often Parkinsonian syndromes), can be triggered by turning, initiating gait, or navigating narrow spaces, and reflects a disruption in the neural control of walking rather than a problem with the legs themselves.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

X-CUE Smart Glasses Ready for Clinical Trials Following Over a Decade of Development

X-CUE Smart

WILMINGTON, Del., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that on November 19, 2026, it entered into a Strategic Business Expansion and Investment Agreement with NeuroQ Biologics Inc. (“NeuroQ”) and Laonz Co., Ltd. (“Laonz”) to expand its business into medical device technologies designed to assist patients with Parkinson’s disease.

The agreement focuses on X-CUE, an augmented-reality smart-glasses technology developed over more than a decade to assist patients with Parkinson’s disease who experience freezing of gait, a condition that can significantly affect mobility and daily activities.

X-CUE augmented-reality smart-glasses technology (product illustration).

X-CUE augmented-reality smart-glasses technology (product illustration).

X-CUE uses augmented-reality visual cues designed to help patients manage freezing-of-gait episodes and support mobility. According to the technology developers, X-CUE has completed its product development phase for the latest, third-revised version of its medical device and is ready for planned clinical trials intended to support commercialization, with an anticipated clinical evaluation period of approximately six months.

Strategic Investment and Business Expansion
Under the agreement, Exicure intends to acquire an equity interest ranging from 20% to 100% in NeuroQ, primarily through the issuance of Exicure common shares in exchange for NeuroQ shares held by Laonz.

The final acquisition percentage, share exchange ratio, and other transaction terms will be determined through subsequent written agreements, subject to applicable corporate and regulatory approvals and Nasdaq requirements.

Following completion of the proposed share acquisition, Exicure intends to provide up to US$500,000 in development funding to support X-CUE’s clinical evaluation, regulatory advancement, manufacturing preparation, and commercialization initiatives, subject to applicable approvals, funding availability, and definitive funding arrangements.

Advancing X-CUE Toward Commercialization
Laonz has completed the transfer of the X-CUE business, including related intellectual property, technology, assets, and business rights, to NeuroQ.

NeuroQ will lead the continued development, clinical evaluation, regulatory approval, and commercialization of X-CUE, with strategic support from Exicure.

The parties intend to leverage the technology’s extensive development history and current product readiness to advance X-CUE through the remaining clinical and regulatory processes toward potential commercialization.

“Through this strategic agreement, we are expanding Exicure’s business into innovative medical device technologies designed to address important unmet needs among patients with Parkinson’s disease,” said Jung Soo Kim, Chief Executive Officer of Exicure. “With more than a decade of development behind X-CUE and the product ready for planned clinical evaluation, we believe this initiative presents a promising opportunity to advance a differentiated technology toward commercialization and create long-term value for our stockholders.”

About X-CUE
X-CUE is an augmented-reality smart-glasses technology designed to assist patients with Parkinson’s disease who experience freezing of gait.

Developed over more than a decade, X-CUE provides visual cues intended to support mobility during freezing-of-gait episodes.

The product has completed its development phase and is being prepared for clinical evaluation, with an anticipated clinical trial period of approximately six months. Potential commercialization remains subject to successful clinical evaluation and applicable regulatory approvals.

About Exicure, Inc.
Exicure, Inc. (Nasdaq: XCUR) is a biotechnology company focused on advancing innovative healthcare technologies and pursuing strategic growth opportunities.

The Company’s portfolio includes a clinical-stage program targeting stem cell mobilization for multiple myeloma, sickle cell disease, and cell and gene therapy applications.

Exicure is expanding its strategic focus to include medical device technologies designed to address unmet needs in Parkinson’s disease and other healthcare markets.

For more information, visit www.exicuretx.com.

Cautionary Note Regarding Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, statements regarding the Company’s proposed acquisition of an equity interest in NeuroQ Biologics Inc., the anticipated issuance of Exicure common shares, potential development funding of up to $500,000, the continued development and clinical evaluation of X-CUE technology, the anticipated six-month clinical evaluation period, potential regulatory approvals, and future commercialization opportunities.

Words such as “plans,” “expects,” “will,” “anticipates,” “continue,” “believes,” “may,” “intend,” “could,” and other words and terms of similar meaning and expression are intended to identify forward-looking statements, although not all forward-looking statements contain such terms.

Forward-looking statements are based on management’s current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results may differ materially due to various factors, including the inability to finalize or complete the proposed acquisition, failure to satisfy applicable closing conditions or obtain required approvals, funding limitations, clinical trial delays or unfavorable results, regulatory uncertainties, and challenges associated with the development and commercialization of X-CUE technology.

For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 25, 2026, as updated by the Company’s subsequent filings with the SEC.

All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

Contact Information
Exicure, Inc.
Investor Relations
Email: pr@exicuretx.com 

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/745faad3-b4c6-4142-903f-8bd8dc930f8e
https://www.globenewswire.com/NewsRoom/AttachmentNg/dd8090ad-20f1-4e98-a4b6-d8ea0268c5eb


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much of NeuroQ does Exicure plan to acquire, and how would it pay?

Exicure intends to acquire a 20% to 100% stake in NeuroQ, primarily by issuing Exicure common shares in exchange for NeuroQ shares held by Laonz. Subsequent written agreements will determine the final stake and share exchange ratio.

What would Exicure’s planned X-CUE development funding pay for?

Exicure intends the funding to support clinical evaluation and regulatory advancement, as well as manufacturing preparation and commercialization initiatives. The company plans to provide up to US$500,000 after the proposed acquisition closes, subject to applicable approvals, funding availability and definitive funding arrangements.

Keep reading